<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232531</url>
  </required_header>
  <id_info>
    <org_study_id>04.OXA.020</org_study_id>
    <nct_id>NCT00232531</nct_id>
  </id_info>
  <brief_title>Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function</brief_title>
  <official_title>Cardiovascular Magnetic Resonance Evaluation of the Effects of Niaspan on Regression of Atherosclerosis and Restoration of Endothelial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <brief_summary>
    <textblock>
      AIM 1 will test the hypothesis that elevation of high-density lipoprotein (HDL) through&#xD;
      treatment with Niaspan will accelerate the regression of atherosclerotic plaque in patients&#xD;
      with established atherosclerosis. The investigators will therefore study patients with&#xD;
      atherosclerosis in the aorta and carotid artery. Plaque quantification will be with magnetic&#xD;
      resonance imaging (MRI).&#xD;
&#xD;
      AIM 2 will assess the ability of Niaspan to improve endothelial function in patients with&#xD;
      coronary artery disease and type II diabetes mellitus, who typically have low high-density&#xD;
      lipoprotein cholesterol (HDL-C), and high risk of cardiovascular events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomised to receive either Niaspan 2000mg each night or placebo. Niaspan&#xD;
      will be commenced at 375mg daily and increased to 500mg then to 750, and 1000mg daily at&#xD;
      weekly intervals. After 4 weeks the dose will be increased to 1500mg daily and, after a&#xD;
      further one month, the study dose of 2000mg daily2 will be instigated. Immediately before&#xD;
      randomization (to exclude patients unable to tolerate MRI because of claustrophobia), and 6&#xD;
      and 12 months after commencing treatment participants will undergo MR examination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2004</start_date>
  <completion_date>February 2009</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regression of artheriosclerotic plaque measured using functional magnetic resonance imaging.</measure>
  </primary_outcome>
  <enrollment>70</enrollment>
  <condition>Atherosclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niaspan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aim 1: Carotid or peripheral arterial disease and HDL &lt;1mmol/L&#xD;
&#xD;
          -  Aim 2: Coronary artery disease, type II diabetes and HDL &lt;1mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The following will constitute exclusion criteria:&#xD;
&#xD;
          -  Inability to provide informed consent,&#xD;
&#xD;
          -  Known intolerance of a study drug,&#xD;
&#xD;
          -  Use of niacin or a fibrate at time of screening,&#xD;
&#xD;
          -  AST or ALT elevated above normal range at time of screening&#xD;
&#xD;
          -  Use of oral nitrates or nicorandil&#xD;
&#xD;
          -  Uncontrolled or newly diagnosed diabetes mellitus&#xD;
&#xD;
          -  Symptomatic heart failure or heart failure requiring treatment with diuretics&#xD;
&#xD;
          -  Fasting triglycerides &gt; 500mg/dL [5.65mmol/L]&#xD;
&#xD;
          -  Patients with acute coronary syndromes, active peptic ulcer disease,&#xD;
&#xD;
          -  Active gout,&#xD;
&#xD;
          -  Standard exclusions for MRI will apply, i.e. pacemakers, implantable defibrillators,&#xD;
             metal implants or embedded metallic fragments of any kind.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin P Choudhury, DM, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oxford University</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>October 3, 2005</study_first_submitted>
  <study_first_submitted_qc>October 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <last_update_submitted>January 26, 2007</last_update_submitted>
  <last_update_submitted_qc>January 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

